Search This Blog

Friday, March 22, 2013

FDA Approves GE Healthcare’s AdreView™ (Iobenguane I 123 Injection) for Cardiac Risk Evaluation in Heart Failure Patients

General Electric media information for journalists and the press - Press-Releases - FDA Approves GE Healthcare’s AdreView™ (Iobenguane I 123 Injection) for Cardiac Risk Evaluation in Heart Failure Patients - General Electric media information for journalists and the press
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)